Reaction
Splenic Infarction reporting signals
As of the last recalculation, Splenic Infarction appears in 1,714 FAERS reports alongside 43 co-occurring drug terms. The strongest observed disproportionality signal is HYDROXYUREA (PRR 26.5).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Hydroxyurea | 45 | 26.5 | 26.6 |
| Azacitidine For | 31 | 21.1 | 21.1 |
| Amphotericin B | 21 | 20.6 | 20.6 |
| Rifampicin | 15 | 18.2 | 18.2 |
| Heparin Sodium | 19 | 17.0 | 17.0 |
| Pyrazinamide | 13 | 16.9 | 17.0 |
| Azacitidine | 38 | 15.9 | 15.9 |
| Bleomycin Sulfate | 13 | 15.4 | 15.4 |
| Minocycline | 11 | 11.5 | 11.5 |
| Phytonadione | 8 | 11.5 | 11.5 |
| Inclisiran | 7 | 10.6 | 10.6 |
| Atovaquone | 7 | 10.6 | 10.6 |
| Isoniazid | 14 | 10.6 | 10.6 |
| Enoxaparin Sodium | 48 | 10.4 | 10.4 |
| Norepinephrine | 9 | 10.3 | 10.3 |
| Ruxolitinib | 56 | 9.8 | 9.8 |
| Drs. Clotrimazole | 9 | 9.5 | 9.5 |
| Family Wellness Clotrimazole | 9 | 9.5 | 9.5 |
| Clotrimazole Topical | 9 | 9.5 | 9.5 |
| Cefepime | 11 | 9.4 | 9.4 |
| Norepinephrine Bitartrate | 11 | 9.3 | 9.3 |
| Remdesivir | 10 | 9.2 | 9.2 |
| Cisplatin | 57 | 9.1 | 9.1 |
| Cefepime Hydrochloride | 12 | 9.1 | 9.1 |
| Rifampin | 10 | 8.4 | 8.4 |
| Gemcitabine Hydrochloride | 35 | 8.2 | 8.2 |
| Alteplase | 10 | 8.1 | 8.1 |
| Romiplostim | 10 | 8.1 | 8.1 |
| Methylphenidate | 19 | 8.0 | 8.1 |
| Eltrombopag Olamine | 15 | 8.0 | 8.0 |
| Deferasirox | 17 | 7.9 | 7.9 |
| Filgrastim | 24 | 7.8 | 7.8 |
| Drospirenone And Ethinyl Estradiol | 28 | 7.8 | 7.8 |
| Venetoclax | 38 | 7.6 | 7.6 |
| Gemcitabine | 24 | 7.5 | 7.5 |
| Aprepitant | 11 | 7.3 | 7.3 |
| Temozolomide | 11 | 6.4 | 6.4 |
| Pegaspargase | 6 | 6.0 | 6.0 |
| Pemetrexed Disodium | 18 | 5.8 | 5.8 |
| Pemetrexed | 10 | 5.7 | 5.7 |
| Gefitinib | 4 | 5.4 | 5.4 |
| Ledipasvir And Sofosbuvir | 7 | 4.4 | 4.4 |
| Pegfilgrastim | 27 | 3.4 | 3.4 |